Oruka Therapeutics (ORKA) Operating Income (2010 - 2024)

Oruka Therapeutics' Operating Income history runs 15 years deep, the most recent figure standing at -$3.1 million for Q2 2024.

• On a quarterly basis, Operating Income fell 58.24% year-over-year to -$3.1 million in Q2 2024; TTM through Jun 2024 was -$9.1 million, a 16.04% decrease from a year earlier, with the FY2023 full-year figure at -$7.3 million, up 31.14% from the prior year.
• Operating Income fell to -$3.1 million in Q2 2024 per ORKA's latest filing, from -$2.5 million in the prior quarter.
• Across five years, Operating Income topped out at -$1.3 million in Q2 2020 and bottomed at -$5.7 million in Q4 2021.
• The 5-year median for Operating Income is -$2.5 million (2022), against an average of -$2.9 million.
• Across the five-year window, Operating Income slumped 301.1% in 2020 and surged 72.75% in 2022, its largest moves.
• Year by year, Operating Income stood at -$5.1 million in 2020, then slipped by 10.81% to -$5.7 million in 2021, then jumped by 72.75% to -$1.5 million in 2022, then dropped by 2.71% to -$1.6 million in 2023, then plunged by 96.35% to -$3.1 million in 2024.
• Per Business Quant, the three latest ORKA Operating Income figures stand at -$3.1 million (Q2 2024), -$2.5 million (Q1 2024), and -$1.6 million (Q4 2023).